Advocacy intelligence hub — real-time data for patient organizations
Biogen
Biogen — PHASE3
Design Therapeutics, Inc. — PHASE1, PHASE2
Centre Hospitalier Universitaire de Nice
IRCCS Eugenio Medea — NA
Design Therapeutics, Inc. — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Skyclarys
Biogen U.S. Corporation
Skyclarys
(omaveloxolone)Orphan drugBiogen U.S. Corporation
12.1 Mechanism of Action The precise mechanism by which omaveloxolone exerts its therapeutic effect in patients with Friedreich's ataxia is unknown. O...
Francesco Saccà, MD
University Federico II, Naples Italy
Alberto Benussi, MD
Università degli Studi di Brescia
📍 Trieste, Trieste
Ronald G Crystal, MD, MD
Weill Medical College of Cornell University
📍 NEW YORK, NY
Thomas Klopstock, MD
Friedrich-Baur-Institute, Department of Neurology, University of Munich Ziemssenstr
Theresa Zesiewicz, MD, MD
University of South Florida
📍 TAMPA, FL
Barbara Borroni, MD
Azienda Ospedaliera Spedali Civili, Brescia